Monday, 19 November 2018

EPILEPSY TREATMENT 2019

About Conference


Conference Series LLC Ltd provides the perfect platform for global networking and our Epilepsy Treatment 2019 conference aims to gather the Professors, Researchers, Business Delegates, and Scientists, students across the globe to provide an international forum for the dissemination of original research results, new ideas, and practical development experiences.

We are truly delighted to invite you to attend the 5th  World Congress on Epilepsy and Treatment, during August 14-15, 2019 at Tokyo, Japan. Epilepsy treatment 2019 will provide two days of robust discussions for the treatment of various types of Epilepsy and its effects in pregnant women, Infantile Seizures, Genetic causes, mutations, and other novels therapeutic and diagnostic approaches of Epilepsy. It will also explore new ideas and concepts on a global scale.

 Epilepsy is the fourth common neurodegenerative disorder and affects people of all ages. Public perception and misunderstanding of epilepsy causes challenges often worse than the seizures.

The seizures in epilepsy can be associated with brain injury or a family tendency, but most of the time the cause is unknown.

 “Seizures are caused by disturbances in the electrical activity of the brain”

Epilepsy is a very common neurodegenerative disorder that affects about 65 million people worldwide. In the United States, 1 in 26 people will develop epilepsy at a few points in their lifetime. Ten out of thousand numbers of people on earth develop active seizures at once in life. In the United State 150,000 number of people lives with epilepsy in each year.1/3rd the number of people with epilepsy who live with uncontrollable seizures because no available treatment works for them. Cause of epilepsy is unknown for those ten people out of six.

Scope & Importance

Epilepsy is a non-communicable disorder of the brain that affects people of all ages. According to WHO (World Health Organization) statistics more than 50 million people are affected in the world. It is estimated that every year nearly 2.4 million people are diagnosed with epilepsy and the population with active epilepsy is between 4 to10 per 1000 people. Approximately 50 million people in the world have epilepsy, nowadays which is one of the common neurological diseases globally. Nearly 80% of people in the world live in low- and middle-income countries with epilepsy. Approximately 70% of the people with epilepsy living in low-and-middle-income countries get treatment as they need & rest of 3/4th people, they do not get. In different parts of the world, many families with epilepsy suffer from stigma and discrimination.

WHY ATTEND THE CONFERENCE

Epilepsy Treatment 2019 conference brings together Speakers and attendees and decision-makers from different biotechnology and medical companies, major pharmaceutical and device companies, and researchers and innovators at the cutting-edge of epilepsy and CNS treatment advances.  Also to create an agenda with highly innovative topics on epilepsy treatment, therapeutic innovation, and product development. Initiate demos, share information, come across with eminent personalities, and create novel antiepileptic line and latest diagnostic methods at this outstanding event.

Targeted audience


  • Epileptologists
  • Neurologists
  • Pharmacists
  • Research scientists
  • Anti- Epileptic drug Industries
  • Epilepsy associations & foundation 
  • Professors and Students from Academia in the study of Epilepsy field.
  • Epilepsy organizations Biopharmaceutical (drug design and discovery) companies

Conference Highlights

Friday, 26 October 2018


Here is the Tentative agenda of Epilepsy Treatment Conference 2018,Tokyo Japan from November 16-17,2018.
https://epilepsy.neurologyconference.com/




Sunday, 30 September 2018

DEA reschedules Epidiolex, marijuana-derived drug, paving the way for it to hit the market

The Drug Enforcement Administration has rescheduled Epidiolex, paving the way for GW Pharmaceuticals to start selling the first FDA-approved drug derived from cannabis, but stopped short of reclassifying all cannabidiol products. The Food and Drug Administration in June approved Epidiolex, which is derived from cannabidiol, or CBD, a molecule contained in the marijuana plant. This forced the DEA to consider how it would classify Epidiolex since marijuana is considered a schedule 1 drug, which it defines as having no currently accepted medical use and a high potential for abuse. Epidiolex will be classified as a schedule 5 controlled substance, the lowest level, defined as those with a proven medical use and low potential for abuse. Other drugs in this category include some cough medicines containing codeine. The drug is indicated to treat patients two years and older with Dravet Syndrome and Lennox-Gastaut Syndrome, rare forms of epilepsy that emerge during childhood and can be difficult to treat. It does not contain tetrahydrocannabinol, or THC, the psychoactive compound in cannabis that makes people high. GW Pharma said it would "work hard" to make Epidiolex available within the next six weeks. Shares of GW Pharma rose 8 percent on the news and helped pot stocks soar.

 

Monday, 24 September 2018

On the Occasion of World Pharmacists Day 
Avail $100 off at 4th World congress on Epilepsy and Treatment 2018 Tokyo Japan,November 16-17,2018.
https://epilepsy.neurologyconference.com/registration.php


Friday, 14 September 2018

Electronic device implanted in the brain could stop seizures 

Source -University of Cambridge 

Researchers have successfully demonstrated how an electronic device implanted directly into the brain can detect, stop and even prevent epileptic seizures.
The researchers, from the University of Cambridge, the École Nationale Supérieure des Mines and INSERM in France, implanted the device into the brains of mice, and when the first signals of a seizure were detected, delivered a native brain chemical which stopped the seizure from progressing. The results, reported in the journal Science Advances, could also be applied to other conditions including brain tumours and Parkinson's disease.
The work represents another advance in the development of soft, flexible electronics that interface well with human tissue. "These thin, organic films do minimal damage in the brain, and their electrical properties are well-suited for these types of applications," said Professor George Malliaras, the Prince Philip Professor of Technology in Cambridge's Department of Engineering, who led the research.
While there are many different types of seizures, in most patients with epilepsy, neurons in the brain start firing and signal to neighbouring neurons to fire as well, in a snowball effect that can affect consciousness or motor control. Epilepsy is most commonly treated with anti-epileptic drugs, but these drugs often have serious side effects and they do not prevent seizures in three out of 10 patients.
In the current work, the researchers used a neurotransmitter which acts as the 'brake' at the source of the seizure, essentially signalling to the neurons to stop firing and end the seizure. The drug is delivered to the affected region of the brain by a neural probe incorporating a tiny ion pump and electrodes to monitor neural activity.
When the neural signal of a seizure is detected by the electrodes, the ion pump is activated, creating an electric field that moves the drug across an ion exchange membrane and out of the device, a process known as electrophoresis. The amount of drug can be controlled by tuning the strength of the electric field.
"In addition to be being able to control exactly when and how much drug is delivered, what is special about this approach is that the drugs come out of the device without any solvent," said lead author Dr Christopher Proctor, a postdoctoral researcher in the Department of Engineering. "This prevents damage to the surrounding tissue and allows the drugs to interact with the cells immediately outside the device."
The researchers found that seizures could be prevented with relatively small doses of drug representing less than 1% of the total amount of drug loaded into the device. This means the device should be able to operate for extended periods without needing to be refilled. They also found evidence that the delivered drug, which was in fact a neurotransmitter that is native to the body, was taken up by natural processes in the brain within minutes which, the researchers say, should help reduce side effects from the treatment.
Although early results are promising, the potential treatment would not be available for humans for several years. The researchers next plan to study the longer-term effects of the device in mice.
Malliaras is establishing a new facility at Cambridge which will be able to prototype these specialised devices, which could be used for a range of conditions. Although the device was tested in an animal model of epilepsy, the same technology could potentially be used for other neurological conditions, including the treatment of brain tumours and Parkinson's disease.